WASHINGTON: Merck's anti-Covid pill remains "active" against the Omicron variant, the US drugmaker said Friday (Jan 28), citing results from six laboratory studies.
The oral treatment, called molnupiravir, is taken within five days of symptom onset and was shown in a pre-Omicron trial of 1,400 participants to reduce Covid hospitalisations and deaths by 30 percent among at-risk people.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
